These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
287 related articles for article (PubMed ID: 18852217)
21. Quantitative and functional expression of somatostatin receptor subtypes in human thymocytes. Ferone D; Pivonello R; Van Hagen PM; Dalm VA; Lichtenauer-Kaligis EG; Waaijers M; Van Koetsveld PM; Mooy DM; Colao A; Minuto F; Lamberts SW; Hofland LJ Am J Physiol Endocrinol Metab; 2002 Nov; 283(5):E1056-66. PubMed ID: 12376335 [TBL] [Abstract][Full Text] [Related]
22. Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells. van der Hoek J; Waaijers M; van Koetsveld PM; Sprij-Mooij D; Feelders RA; Schmid HA; Schoeffter P; Hoyer D; Cervia D; Taylor JE; Culler MD; Lamberts SW; Hofland LJ Am J Physiol Endocrinol Metab; 2005 Aug; 289(2):E278-87. PubMed ID: 15769796 [TBL] [Abstract][Full Text] [Related]
23. Somatostatin and dopamine receptors as targets for medical treatment of Cushing's Syndrome. de Bruin C; Feelders RA; Lamberts SW; Hofland LJ Rev Endocr Metab Disord; 2009 Jun; 10(2):91-102. PubMed ID: 18642088 [TBL] [Abstract][Full Text] [Related]
24. The role of somatostatin and dopamine D2 receptors in endocrine tumors. Gatto F; Hofland LJ Endocr Relat Cancer; 2011 Dec; 18(6):R233-51. PubMed ID: 22135243 [TBL] [Abstract][Full Text] [Related]
25. Highly efficient in vivo agonist-induced internalization of sst2 receptors in somatostatin target tissues. Waser B; Tamma ML; Cescato R; Maecke HR; Reubi JC J Nucl Med; 2009 Jun; 50(6):936-41. PubMed ID: 19443580 [TBL] [Abstract][Full Text] [Related]
26. Deficiency of somatostatin (SST) receptor type 5 (SSTR5) is associated with sexually dimorphic changes in the expression of SST and SST receptors in brain and pancreas. Ramírez JL; Grant M; Norman M; Wang XP; Moldovan S; de Mayo FJ; Brunicardi C; Kumar U Mol Cell Endocrinol; 2004 Jun; 221(1-2):105-19. PubMed ID: 15223137 [TBL] [Abstract][Full Text] [Related]
27. Glucocorticoids inhibit somatostatin gene expression through accelerated degradation of somatostatin messenger ribonucleic acid in human thyroid medullary carcinoma (TT) cells. Liu JL; Patel YC Endocrinology; 1995 Jun; 136(6):2389-96. PubMed ID: 7750460 [TBL] [Abstract][Full Text] [Related]
28. Expression of Somatostatin, cortistatin, and their receptors, as well as dopamine receptors, but not of neprilysin, are reduced in the temporal lobe of Alzheimer's disease patients. Gahete MD; Rubio A; Durán-Prado M; Avila J; Luque RM; Castaño JP J Alzheimers Dis; 2010; 20(2):465-75. PubMed ID: 20164562 [TBL] [Abstract][Full Text] [Related]
29. RT-PCR and immunocytochemistry studies support the presence of somatostatin, cortistatin and somatostatin receptor subtypes in rat Kupffer cells. Xidakis C; Mastrodimou N; Notas G; Renieri E; Kolios G; Kouroumalis E; Thermos K Regul Pept; 2007 Oct; 143(1-3):76-82. PubMed ID: 17481746 [TBL] [Abstract][Full Text] [Related]
30. Medical treatment of Cushing's disease: somatostatin analogues and pasireotide. Pedroncelli AM Neuroendocrinology; 2010; 92 Suppl 1():120-4. PubMed ID: 20829632 [TBL] [Abstract][Full Text] [Related]
31. The role of somatostatin analogs in Cushing's disease. van der Hoek J; Lamberts SW; Hofland LJ Pituitary; 2004; 7(4):257-64. PubMed ID: 16132202 [TBL] [Abstract][Full Text] [Related]
32. Somatostatin modulates dopamine release in rat retina. Kouvidi E; Papadopoulou-Daifoti Z; Thermos K Neurosci Lett; 2006 Jan; 391(3):82-6. PubMed ID: 16183196 [TBL] [Abstract][Full Text] [Related]
33. The somatostatin receptor subtype 5 in neuroendocrine tumours. van der Hoek J; Lamberts SW; Hofland LJ Expert Opin Investig Drugs; 2010 Mar; 19(3):385-99. PubMed ID: 20151855 [TBL] [Abstract][Full Text] [Related]
34. Glucocorticoids differentially regulate expression of duodenal and renal calbindin-D9k through glucocorticoid receptor-mediated pathway in mouse model. Lee GS; Choi KC; Jeung EB Am J Physiol Endocrinol Metab; 2006 Feb; 290(2):E299-307. PubMed ID: 16219669 [TBL] [Abstract][Full Text] [Related]
35. Investigation of cancer cell lines for peptide receptor-targeted drug development. Sun L; Luo J; Mackey LV; Morris LM; Franko-Tobin LG; LePage KT; Coy DH J Drug Target; 2011 Sep; 19(8):719-30. PubMed ID: 21830941 [TBL] [Abstract][Full Text] [Related]
36. Somatostatin receptors in wildtype and somatostatin deficient mice and their involvement in nitric oxide physiology in the retina. Mastrodimou N; Vasilaki A; Papadioti A; Low MJ; Hoyer D; Thermos K Neuropeptides; 2006 Oct; 40(5):365-73. PubMed ID: 17010429 [TBL] [Abstract][Full Text] [Related]
37. Reassessment of sst(5) somatostatin receptor expression in normal and neoplastic human tissues using the novel rabbit monoclonal antibody UMB-4. Lupp A; Hunder A; Petrich A; Nagel F; Doll C; Schulz S Neuroendocrinology; 2011; 94(3):255-64. PubMed ID: 21952553 [TBL] [Abstract][Full Text] [Related]
38. Mifepristone effects on tumor somatostatin receptor expression in two patients with Cushing's syndrome due to ectopic adrenocorticotropin secretion. de Bruin C; Hofland LJ; Nieman LK; van Koetsveld PM; Waaijers AM; Sprij-Mooij DM; van Essen M; Lamberts SW; de Herder WW; Feelders RA J Clin Endocrinol Metab; 2012 Feb; 97(2):455-62. PubMed ID: 22090282 [TBL] [Abstract][Full Text] [Related]
40. The somatostatin receptor (sst1) modulates the release of somatostatin in the nucleus accumbens of the rat. Vasilaki A; Papasava D; Hoyer D; Thermos K Neuropharmacology; 2004 Sep; 47(4):612-8. PubMed ID: 15380378 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]